Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic cardiac disease characterized by progressive myocardial fibro-fatty replacement, arrhythmias and risk of sudden death. Its diagnosis is challenging and often it is achieved after disease onset or postmortem. In this study, we sought...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/10/2578 |
| _version_ | 1797515024113074176 |
|---|---|
| author | Claudia Sacchetto Zenab Mohseni Robin M. W. Colpaert Libero Vitiello Marzia De Bortoli Indira G. C. Vonhögen Ke Xiao Giulia Poloni Alessandra Lorenzon Chiara Romualdi Riccardo Bariani Elisa Mazzotti Luciano Daliento Barbara Bauce Domenico Corrado Thomas Thum Alessandra Rampazzo Leon J. de Windt Martina Calore |
| author_facet | Claudia Sacchetto Zenab Mohseni Robin M. W. Colpaert Libero Vitiello Marzia De Bortoli Indira G. C. Vonhögen Ke Xiao Giulia Poloni Alessandra Lorenzon Chiara Romualdi Riccardo Bariani Elisa Mazzotti Luciano Daliento Barbara Bauce Domenico Corrado Thomas Thum Alessandra Rampazzo Leon J. de Windt Martina Calore |
| author_sort | Claudia Sacchetto |
| collection | DOAJ |
| description | Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic cardiac disease characterized by progressive myocardial fibro-fatty replacement, arrhythmias and risk of sudden death. Its diagnosis is challenging and often it is achieved after disease onset or postmortem. In this study, we sought to identify circulating microRNAs (miRNAs) differentially expressed in ARVC patients compared to healthy controls. In the pilot study, we screened the expression of 754 miRNAs from 21 ARVC patients and 20 healthy controls. After filtering the miRNAs considering a log fold-change cut-off of ±1, <i>p</i>-value < 0.05, we selected five candidate miRNAs for a subsequent validation study in which we used TaqMan-based real-time PCR to analyse samples from 37 ARVC patients and 30 healthy controls. We found miR-185-5p significantly upregulated in ARVC patients. Receiver operating characteristic analysis indicated an area under the curve of 0.854, corroborating the link of this miRNA and ARVC pathophysiology. |
| first_indexed | 2024-03-10T06:39:45Z |
| format | Article |
| id | doaj.art-a7b2edaafb064e229e4299c489adc425 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T06:39:45Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-a7b2edaafb064e229e4299c489adc4252023-11-22T17:45:51ZengMDPI AGCells2073-44092021-09-011010257810.3390/cells10102578Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular CardiomyopathyClaudia Sacchetto0Zenab Mohseni1Robin M. W. Colpaert2Libero Vitiello3Marzia De Bortoli4Indira G. C. Vonhögen5Ke Xiao6Giulia Poloni7Alessandra Lorenzon8Chiara Romualdi9Riccardo Bariani10Elisa Mazzotti11Luciano Daliento12Barbara Bauce13Domenico Corrado14Thomas Thum15Alessandra Rampazzo16Leon J. de Windt17Martina Calore18Department of Molecular Genetics, Faculty of Science and Engineering, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The NetherlandsDepartment of Molecular Genetics, Faculty of Science and Engineering, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The NetherlandsDepartment of Molecular Genetics, Faculty of Science and Engineering, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The NetherlandsDepartment of Biology, Padova University, 35121 Padova, ItalyDepartment of Biology, Padova University, 35121 Padova, ItalyDepartment of Molecular Genetics, Faculty of Science and Engineering, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The NetherlandsInstitute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, D-30625 Hannover, GermanyDepartment of Biology, Padova University, 35121 Padova, ItalyDepartment of Biology, Padova University, 35121 Padova, ItalyDepartment of Biology, Padova University, 35121 Padova, ItalyDepartment of Cardiac, Thoracic, and Vascular Sciences, Padova University, 35121 Padova, ItalyDepartment of Cardiac, Thoracic, and Vascular Sciences, Padova University, 35121 Padova, ItalyDepartment of Cardiac, Thoracic, and Vascular Sciences, Padova University, 35121 Padova, ItalyDepartment of Cardiac, Thoracic, and Vascular Sciences, Padova University, 35121 Padova, ItalyDepartment of Cardiac, Thoracic, and Vascular Sciences, Padova University, 35121 Padova, ItalyInstitute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, D-30625 Hannover, GermanyDepartment of Biology, Padova University, 35121 Padova, ItalyDepartment of Molecular Genetics, Faculty of Science and Engineering, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The NetherlandsDepartment of Molecular Genetics, Faculty of Science and Engineering, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The NetherlandsArrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic cardiac disease characterized by progressive myocardial fibro-fatty replacement, arrhythmias and risk of sudden death. Its diagnosis is challenging and often it is achieved after disease onset or postmortem. In this study, we sought to identify circulating microRNAs (miRNAs) differentially expressed in ARVC patients compared to healthy controls. In the pilot study, we screened the expression of 754 miRNAs from 21 ARVC patients and 20 healthy controls. After filtering the miRNAs considering a log fold-change cut-off of ±1, <i>p</i>-value < 0.05, we selected five candidate miRNAs for a subsequent validation study in which we used TaqMan-based real-time PCR to analyse samples from 37 ARVC patients and 30 healthy controls. We found miR-185-5p significantly upregulated in ARVC patients. Receiver operating characteristic analysis indicated an area under the curve of 0.854, corroborating the link of this miRNA and ARVC pathophysiology.https://www.mdpi.com/2073-4409/10/10/2578arrhythmogenic right ventricular cardiomyopathyMicroRNAscirculating microRNAsheart failurebiomarkersgenetics |
| spellingShingle | Claudia Sacchetto Zenab Mohseni Robin M. W. Colpaert Libero Vitiello Marzia De Bortoli Indira G. C. Vonhögen Ke Xiao Giulia Poloni Alessandra Lorenzon Chiara Romualdi Riccardo Bariani Elisa Mazzotti Luciano Daliento Barbara Bauce Domenico Corrado Thomas Thum Alessandra Rampazzo Leon J. de Windt Martina Calore Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy Cells arrhythmogenic right ventricular cardiomyopathy MicroRNAs circulating microRNAs heart failure biomarkers genetics |
| title | Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy |
| title_full | Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy |
| title_fullStr | Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy |
| title_full_unstemmed | Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy |
| title_short | Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy |
| title_sort | circulating mir 185 5p as a potential biomarker for arrhythmogenic right ventricular cardiomyopathy |
| topic | arrhythmogenic right ventricular cardiomyopathy MicroRNAs circulating microRNAs heart failure biomarkers genetics |
| url | https://www.mdpi.com/2073-4409/10/10/2578 |
| work_keys_str_mv | AT claudiasacchetto circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT zenabmohseni circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT robinmwcolpaert circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT liberovitiello circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT marziadebortoli circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT indiragcvonhogen circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT kexiao circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT giuliapoloni circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT alessandralorenzon circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT chiararomualdi circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT riccardobariani circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT elisamazzotti circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT lucianodaliento circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT barbarabauce circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT domenicocorrado circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT thomasthum circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT alessandrarampazzo circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT leonjdewindt circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy AT martinacalore circulatingmir1855pasapotentialbiomarkerforarrhythmogenicrightventricularcardiomyopathy |